Corcept TherapeuticsCORT
CORT
About: Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.
Employees: 500
0
Funds holding %
of 7,312 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
220% more funds holding in top 10
Funds holding in top 10: 5 [Q4 2024] → 16 (+11) [Q1 2025]
140% more first-time investments, than exits
New positions opened: 101 | Existing positions closed: 42
115% more capital invested
Capital invested by funds: $4.24B [Q4 2024] → $9.13B (+$4.89B) [Q1 2025]
13% more funds holding
Funds holding: 365 [Q4 2024] → 414 (+49) [Q1 2025]
9% less repeat investments, than reductions
Existing positions increased: 127 | Existing positions reduced: 140
2.42% less ownership
Funds ownership: 80.38% [Q4 2024] → 77.96% (-2.42%) [Q1 2025]
42% less call options, than puts
Call options by funds: $193M | Put options by funds: $335M
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$145
102%
upside
Avg. target
$145
102%
upside
High target
$145
102%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Swayampakula Ramakanth | 102%upside $145 | Buy Maintained | 6 May 2025 |
Financial journalist opinion
Based on 3 articles about CORT published over the past 30 days
Positive
Seeking Alpha
1 week ago
Beyond Cushing's: The Undervalued Potential Of Corcept's Cortisol Modulators
Applications of Relacorilant and Corcept's other cortisol modulators are not being valued by investors. Results from the Rosella clinical trials showcase the multifaceted applications of cortisol modulators for rare diseases. Korlym's steady revenue growth can support Corcept's increased R&D for the foreseeable future.
Neutral
Business Wire
2 weeks ago
Corcept Presents Data from Treatment Phase of CATALYST Trial at American Diabetes Association's 85th Scientific Sessions with Simultaneous Publication in Diabetes Care
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today presented data from the randomized, double-blind, placebo-controlled treatment phase of its CATALYST trial of Korlym® in patients with hypercortisolism (Cushing's syndrome) and difficult-to-co.
Positive
Seeking Alpha
4 weeks ago
Corcept: Remains A Strong Buy On Recent Weakness And Aggressive Sales Force Hiring
Corcept Therapeutics remains a strong buy, with recent stock weakness attributed to put options trading rather than fundamental issues. Management maintains aggressive 2025 and long-term revenue guidance, supported by increased testing, salesforce expansion, and a backlog of prescriptions. The company is submitting a New Drug Application for Relacorilant in ovarian cancer, opening a new oncology revenue stream beyond endocrinology.
Negative
Market Watch
1 month ago
20 stocks you should avoid — no matter how well the market does
These hard-to-short stocks are likely to lose money, researchers found.
Neutral
Business Wire
1 month ago
Corcept Presents Results from Phase 2 Study of Dazucorilant in Patients with Amyotrophic Lateral Sclerosis (ALS) at ENCALS 2025 Annual Meeting
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, presented results from its DAZALS study of dazucorilant in patients with ALS at the European Network to Cure ALS (ENCALS) 2025 annual meeting. The presentation can be found here. DAZALS is a randomi.
Neutral
Business Wire
1 month ago
Corcept Presents Pivotal Clinical Data in ASCO Late-Breaker with Simultaneous Publication in The Lancet: Relacorilant Improves Progression-Free and Overall Survival in Patients with Platinum-Resistant Ovarian Cancer
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer in a late-breaking oral presentation at the ASCO 2025.
Negative
Zacks Investment Research
1 month ago
New Strong Sell Stocks for May 29th
CORT, AETUF and MITT have been added to the Zacks Rank #5 (Strong Sell) List on May 29, 2025.
Neutral
Zacks Investment Research
2 months ago
CORT's Q1 Earnings In Line With Estimates, Revenues Lag, Shares Fall
Corcept's first-quarter 2025 earnings meet estimates while revenues miss the same. The company reiterates its revenue guidance for 2025.
Neutral
Seeking Alpha
2 months ago
Corcept Therapeutics Incorporated (CORT) Q1 2025 Earnings Call Transcript
Corcept Therapeutics Incorporated (NASDAQ:CORT ) Q1 2025 Earnings Conference Call May 5, 2025 5:00 PM ET Company Participants Atabak Mokari - Chief Financial Officer Sean Maduck - President, Endocrinology Charlie Robb - Chief Business Officer Joe Belanoff - Chief Executive Officer Roberto Vieira - President, Oncology Bill Guyer - Chief Development Officer Conference Call Participants Edward Nash - Canaccord David Amsellem - Piper Sandler Joon Lee - Truist Securities RK - H. C. Wainwright Operator Thank you for standing by.
Positive
Zacks Investment Research
2 months ago
Corcept Therapeutics (CORT) Meets Q1 Earnings Estimates
Corcept Therapeutics (CORT) came out with quarterly earnings of $0.17 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.25 per share a year ago.
Charts implemented using Lightweight Charts™